Australia | Dec 11 2020
This story features HEALIUS LIMITED. For more info SHARE ANALYSIS: HLS
Having divested of its medical centres, Healius has initiated a buyback, revised its dividend policy and outlined new profitability targets
-Around $80m in savings targeted by FY23
-Risks from rapid fall in covid-19 testing
-Assets under earning at present
By Eva Brocklehurst
In the aftermath of its medical centres divestment, Healius ((HLS)) has offered no new strategic initiatives, although has confirmed intentions regarding optimising the existing business and strengthening its day hospital specialty.
Having received $483m in proceeds from the sale of the medical centres the company will allocate a portion to debt repayment and now has a solid balance sheet that affords room for capital management.
Capital management plans include a $200m buyback and the dividend policy has been revised to 50-70% of reported net profit. Credit Suisse calculates around $600m in excess capacity for acquisitions before Healius reaches its target gearing range.
The broker also estimates, if all cost reductions are achieved and the share buyback completed, this could result in 15% growth in earnings per share from FY19-23. Given the high level of execution risk, particularly as savings centre on labour management, the broker is more modest in its forecasts and assumes 13% growth.
Under its sustainable improvement program Healius expects $80m of annualised savings by FY23. Ord Minnett suspects this is ambitious but highlights the size of the opportunities, with a potential 40-50% boost to earnings from cost savings over the next 2.5 years.
The company has earmarked $50-100m for acquisitions and the broker has been encouraged by recent results from the Monserrat day hospital, although acknowledges it is too early to judge this venture a success.
Healius has signalled more than 300 basis points of margin upside is in the wings from its profitability improvements. New targets for pathology and imaging earnings (EBIT) are $180-$190m and $60-65m, respectively.
Citi forecasts a more muted 100 basis points margin increase, given execution risk and the mixed track record. While the pathology and imaging assets have strong positions in defensive and growing markets the broker is less convinced about the expansion into day hospitals.
UBS anticipates earnings margins will remain elevated albeit below the 16.5% experienced in the first quarter. This view stems from a more “normalised” revenue mix.
Healius has delayed the implementation of a laboratory information system by a year, to FY24, and the total cost is now expected to be $105-110m for an annual benefit of $15-20m from FY24.
Having been freed from the underperforming medical centres, Morgan Stanley assesses the investment case centres on quantifying the benefit from continued coronavirus testing and the deployment of capital from a de-leveraged balance sheet. Critical to sustaining the share price will be confirmation the company can hit margin targets.
Macquarie agrees the opportunities for margin improvement underpin a positive investment view, as well as the growth options that reflect an improved position for the balance sheet.
Strong growth in pathology throughout October and November has been underpinned by coronavirus testing and the company is dealing with 7,000-10,000 tests per working day.
Goldman Sachs calculates that number would drive an annualised revenue contribution of $100m, and probably at an accretive margin. The base pathology business has also recovered but remains flat. Goldman Sachs forecasts 14% organic pathology growth in FY21, including coronavirus testing.
In imaging, growth has occurred in all states. Importantly, revenue in Victoria in November was ahead of the prior November as restrictions are eased. South Australian revenue, while affected temporarily by the short lockdown, is still above the prior November.
The risks going forward include a likely rapid drop in coronavirus testing in 2021 and the investment in laboratory information systems, although both can be managed in Ord Minnett's view and the stock provides good value relative to a basket of peers in similar sectors.
Citi asserts the remaining assets are likely to be attractive to private equity, as a bidder could generate a 20% internal rate of return over five years after buying the stock for $4.50. The broker retains a Neutral rating on valuation but acknowledges potential for bidders to pay a higher price, as the assets are under-earning at present.
Goldman Sachs believes Healius is one of the few value-oriented stocks in the ASX healthcare sector and should be considered a core holding. The broker, not one of the seven stockbrokers monitored daily on the FNArena database, reiterates a Buy rating with a $4.40 target.
The database has three Buy ratings and three Hold. The consensus target is $4.11, signalling 2.6% upside to the last share price. Targets range from $3.53 (Morgans, yet to comment on the update) to $4.35 (Ord Minnett, Macquarie).
Find out why FNArena subscribers like the service so much: "Your Feedback (Thank You)" – Warning this story contains unashamedly positive feedback on the service provided.
FNArena is proud about its track record and past achievements: Ten Years On
For more info SHARE ANALYSIS: HLS - HEALIUS LIMITED